港股異動 | 康希諾生物(6185.HK)漲8.6% 墨西哥同意購買其生產的3500萬劑疫苗
格隆匯12月10日丨康希諾生物-B(6185.HK)午後直線拉昇後維持在高位震盪,現報182港元,漲幅8.66%,最新總市值450.36億港元;公司A股盤中一度衝高漲13%,收漲10.12%,報438.28元,換手率13.7%。消息稱,墨西哥外交大臣埃塞拉德9日表示,該國衞生部已簽署一項協議,同意購買3500萬劑中國康希諾生物生產的疫苗。埃塞拉德已在推特上宣佈這一消息,並表示墨西哥將在本週內達成交易。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.